These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 21159899)

  • 1. Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes.
    Miao Y; Smink PA; de Zeeuw D; Lambers Heerspink HJ
    Clin Chem; 2011 Feb; 57(2):186-95. PubMed ID: 21159899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Interplay between Fasting Glucose, Echocardiography, and Biomarkers: Pathophysiological Considerations and Prognostic Implications.
    Pareek M
    Dan Med J; 2017 Sep; 64(9):. PubMed ID: 28874244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prediction of the renal and cardiovascular efficacy of aliskiren in ALTITUDE using short-term changes in multiple risk markers.
    Smink PA; Hoekman J; Grobbee DE; Eijkemans MJ; Parving HH; Persson F; Ibsen H; Lindholm L; Wachtell K; de Zeeuw D; Heerspink HJ
    Eur J Prev Cardiol; 2014 Apr; 21(4):434-41. PubMed ID: 23467676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal and cardio-protective effects of direct renin inhibition: a systematic literature review.
    Lambers Heerspink HJ; Perkovic V; de Zeeuw D
    J Hypertens; 2009 Dec; 27(12):2321-31. PubMed ID: 19727007
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.
    Studney D
    Can J Cardiol; 2002 May; 18 Suppl A():3A-6A. PubMed ID: 12045787
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes management: More than just cardiovascular risk?
    Zimmerman RS; Pantalone KM
    Cleve Clin J Med; 2014 Nov; 81(11):672-6. PubMed ID: 25368217
    [No Abstract]   [Full Text] [Related]  

  • 9. Cardiovascular and renal protection in type 2 diabetes mellitus: the role of calcium channel blockers.
    Nosadini R; Tonolo G
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S216-23. PubMed ID: 12466317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin-converting enzyme inhibitors versus AT1 receptor antagonist in cardiovascular and renal protection: the case for AT1 receptor antagonist.
    Berl T
    J Am Soc Nephrol; 2004 Jan; 15 Suppl 1():S71-6. PubMed ID: 14684677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [What do large clinical trials learn us about cardiovascular and renal prevention in patients with type 2 diabetes mellitus and hypertension?].
    Dussol B; Berland Y
    Nephrol Ther; 2006 May; 2(2):51-74. PubMed ID: 16895717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-term Effects of Losartan on Cardiovascular Risk and Allograft Injury Biomarkers in Kidney Transplant Recipients.
    Kuźmiuk-Glembin I; Heleniak Z; Pięta R; Głyda M; Lizakowski S; Renke M; Konopa J; Chamienia A; Biedunkiewicz B; Rutkowski B; Tylicki L; Dębska-Ślizień A
    Transplant Proc; 2022 May; 54(4):981-988. PubMed ID: 35346485
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The importance of short-term off-target effects in estimating the long-term renal and cardiovascular protection of angiotensin receptor blockers.
    Smink PA; Miao Y; Eijkemans MJ; Bakker SJ; Raz I; Parving HH; Hoekman J; Grobbee DE; de Zeeuw D; Lambers Heerspink HJ
    Clin Pharmacol Ther; 2014 Feb; 95(2):208-15. PubMed ID: 24067744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal and cardiovascular protection in type 2 diabetes mellitus: angiotensin II receptor blockers.
    Deferrari G; Ravera M; Deferrari L; Vettoretti S; Ratto E; Parodi D
    J Am Soc Nephrol; 2002 Nov; 13 Suppl 3():S224-9. PubMed ID: 12466318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. When hypertension and diabetes coexist: strategies for cardiorenal protection.
    Weber MA
    Postgrad Med; 2000 Oct; 108(5 Suppl):12-8. PubMed ID: 19667536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is a reduction in albuminuria associated with renal and cardiovascular protection? A post hoc analysis of the ALTITUDE trial.
    Heerspink HJ; Ninomiya T; Persson F; Brenner BM; Brunel P; Chaturvedi N; Desai AS; Haffner SM; Mcmurray JJ; Solomon SD; Pfeffer MA; Parving HH; de Zeeuw D
    Diabetes Obes Metab; 2016 Feb; 18(2):169-77. PubMed ID: 26511599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.